A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

Vial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E -- Leading key opinion leaders (KOL ...

NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to ...

Vir Biotechnology is handing off certain commercial rights for its hepatitis D program to European specialty pharma Norgine ...

Arrowhead Pharma doses first subjects in phase 1/2a study of ARO-MAPT to treat Alzheimer’s disease and other tauopathies: Pasadena, California Thursday, December 11, 2025, 12:00 ...

Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...

Subject to TSX Venture Exchange (“ TSXV ”) approval, NurExone has engaged Russo Partners LLC, a New York–based strategic communications firm, (“ Russo ”) for an initial consulting project for up to ...

Norgine inks exclusive licensing agreement with Vir Biotechnology to enhance hepatology and specialty portfolio: Uxbridge, England Friday, December 19, 2025, 14:00 Hrs [IST] Norgi ...

Analysts are intrested in these 5 stocks: ( ($IBIO) ), ( ($RLMD) ), ( ($SEE) ), ( ($OLLI) ) and ( ($IVVD) ). Here is a breakdown of their recent ...

Bicycle Therapeutics plc , a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced it has ...

ProMIS Neurosciences Inc. , a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in ...